PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31519584-0	2019	Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.	brexpiprazole	0-13	baculoviral IAP repeat-containing 5	Mus musculus	22-30	
31519584-2	2019	Recently, brexpiprazole, an antipsychotic drug, was reported to chemosensitize glioma cells to osimertinib, a third-generation EGFR-TKI, by suppressing survivin, an anti-apoptotic protein, but their combinational effects on lung and pancreatic cancers remain unknown.	brexpiprazole	10-23	baculoviral IAP repeat-containing 5	Mus musculus	152-160	
31191825-8	2019	In the cancer cells and the CSCs, brexpiprazole reduced the expression of survivin, an anti-apoptotic protein, whose reduction sensitizes tumor cells to chemotherapeutic reagents.	brexpiprazole	34-47	baculoviral IAP repeat-containing 5	Mus musculus	74-82	
31191825-9	2019	In the preclinical model in which pancreatic CSCs were subcutaneously implanted into nude mice, brexpiprazole suppressed tumor growth, in addition to reducing the expression of Sox2, a marker for CSCs, and survivin.	brexpiprazole	96-109	baculoviral IAP repeat-containing 5	Mus musculus	206-214